These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32426479)

  • 21. Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for L-DOPA-induced dyskinesia.
    Alcacer C; Charbonnier-Beaupel F; Corvol JC; Girault JA; Hervé D
    Neurosci Lett; 2014 Nov; 583():76-80. PubMed ID: 25233866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
    Xiao D; Cassin JJ; Healy B; Burdett TC; Chen JF; Fredholm BB; Schwarzschild MA
    Brain Res; 2011 Jan; 1367():310-8. PubMed ID: 20828543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
    Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
    J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
    Klietz M; Keber U; Carlsson T; Chiu WH; Höglinger GU; Weihe E; Schäfer MK; Depboylu C
    Neuroscience; 2016 Sep; 331():120-33. PubMed ID: 27320210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's disease.
    Choi H; Koh SH
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):83-90. PubMed ID: 29233065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
    Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ
    Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
    Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
    Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
    Subramaniam S; Napolitano F; Mealer RG; Kim S; Errico F; Barrow R; Shahani N; Tyagi R; Snyder SH; Usiello A
    Nat Neurosci; 2011 Dec; 15(2):191-3. PubMed ID: 22179112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
    Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
    Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [L-dopa induced dyskinesia in Parkinson's disease].
    Bastide MF; Bézard E
    Bull Acad Natl Med; 2015; 199(2-3):201-12. PubMed ID: 27476302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
    Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
    Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.